Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 1080-1084

  Ullmann, Andrew J ^a   Krammes, Erik ^a   Sommer, Sita ^a   Buschmann, Ines ^a   Jahn Muehl, Bernhard ^b   Cacciapuoti, Anthony ^c   Schmitt, Heinz Josef ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Horst Schmidt Klinik   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Animal models; Aspergillus fumigatus; Azoles; Polyenes

Indexed keywords

AMPHOTERICIN B; DEXAMETHASONE; DOXYCYCLINE; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; CONIDIUM; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS CULTURE; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LUNG ASPERGILLOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RAT; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; IMMUNOCOMPROMISED HOST; MALE; MICROBIAL SENSITIVITY TESTS; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 35449003332     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm328     Document Type: Article

References (21)

1. Denning DW. Treatment of invasive aspergillosis. J Infect 1994; 28 Suppl 1: 25-33.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-66.
3. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
4. Pfaller MA, Diekema DJ, Messer SA et al. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole. J Clin Microbiol 2002; 40: 1694-7.
5. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole-voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
6. Ullmann AJ, Sanz MA, Tramarin A et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43: E29-38.
7. Yang DJ, Rankin, GO. Nephrotoxicity of antifungal agents. Adverse Drug React Acute Poisoning Rev 1985; 4: 37-47.
8. Schmitt HJ, Andrade J, Edwards F et al. Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur J Clin Microbiol Infect Dis 1990; 9: 832-5.
9. Schmitt HJ, Bernard EM, Hauser M et al. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988; 32: 1676-9.
10. Schmitt HJ, Bernard EM, Andrade J et al. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32: 780-1.
11. Pfaller MA, Messer SA, Boyken L et al. In vitro susceptibility testing of filamentous fungi: Comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis 2003; 45: 241-4.
12. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol. Rev 1999; 12: 310-50.
13. Kirkpatrick WR, McAtee RK, Fothergill AW et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 780-2.
14. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
15. Martino R, Subira M. Invasive fungal infections in hematology: New trends. Ann Hematol 2002; 81: 233-43.
16. Niki Y, Bernard EM, Edwards FF et al. Model of recurrent pulmonary aspergillosis in rats. J Clin Microbiol 1991; 29: 1317-22.
17. Nomeir AA, Kumari P, Hilbert MJ et al. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 2000; 44: 727-31.
18. Cacciapuoti A, Loebenberg D, Corcoran E et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44: 2017-22.
19. Graybill JR, Bocanegra R, Najvar LK et al. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998; 42 539-42.
20. Oaldey KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1504-7.
21. Patera AC, Menzel F, Jackson C et al. Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob Agents Chemother 2004; 48: 3154-8.